{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T07:26:38Z","timestamp":1787037998828,"version":"build-2736575974"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s00228-026-04145-0","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T02:48:32Z","timestamp":1784861312000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Most COVID-19 vaccine adverse events detected within 48\u00a0hours in Ethiopia: implications for cohort event monitoring efficiency in resource-limited settings"],"prefix":"10.1007","volume":"82","author":[{"given":"Tigist Dires","family":"Gebreyesus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teshita","family":"Shute","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asnakech","family":"Alemu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alemseged Beyene","family":"Berha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehiret","family":"Maru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Habtamu","family":"Gashaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meron","family":"Kifle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Doherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Figueras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"key":"4145_CR1","unstructured":"Guidance on Development and Implementation of a National Deployment (2025) and Vaccination Plan for Vaccines against Pandemic Influenza and Other Respiratory Viruses of Pandemic Potential Available online: https:\/\/www.who.int\/publications\/i\/item\/9789240084872 (accessed on 22 December)"},{"key":"4145_CR2","doi-asserted-by":"publisher","first-page":"e014544","DOI":"10.1136\/bmjgh-2023-014544","volume":"9","author":"RE Chandler","year":"2024","unstructured":"Chandler RE, Balakrishnan MR, Brasseur D, Bryan P, Espie E, Hartmann K, Jouquelet-Royer C, Milligan J, Nesbitt L, Pal S et al (2024) Collaboration within the Global Vaccine Safety Surveillance Ecosystem during the COVID-19 Pandemic: Lessons Learnt and Key Recommendations from the COVAX Vaccine Safety Working Group. BMJ Glob Health 9:e014544. https:\/\/doi.org\/10.1136\/bmjgh-2023-014544","journal-title":"BMJ Glob Health"},{"key":"4145_CR3","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1016\/j.vaccine.2024.01.100","volume":"42","author":"K Faksova","year":"2024","unstructured":"Faksova K, Walsh D, Jiang Y, Griffin J, Phillips A, Gentile A, Kwong JC, Macartney K, Naus M, Grange Z et al (2024) COVID-19 Vaccines and Adverse Events of Special Interest: A Multinational Global Vaccine Data Network (GVDN) Cohort Study of 99 Million Vaccinated Individuals. Vaccine 42:2200\u20132211. https:\/\/doi.org\/10.1016\/j.vaccine.2024.01.100","journal-title":"Vaccine"},{"key":"4145_CR4","doi-asserted-by":"publisher","first-page":"100485","DOI":"10.1016\/j.jvacx.2024.100485","volume":"18","author":"PA ShamaeiZadeh","year":"2024","unstructured":"ShamaeiZadeh PA, Jaimes CV, Knoll MD, Espi\u00e9 E, Chandler RE (2024) Landscape Review of Active Vaccine Safety Surveillance Activities for COVID-19 Vaccines Globally. Vaccine X 18:100485. https:\/\/doi.org\/10.1016\/j.jvacx.2024.100485","journal-title":"Vaccine X"},{"key":"4145_CR5","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1136\/bmj.39323.586123.BE","volume":"335","author":"M Pirmohamed","year":"2007","unstructured":"Pirmohamed M, Atuah KN, Dodoo ANO, Winstanley P (2007) Pharmacovigilance in Developing Countries. BMJ 335:462. https:\/\/doi.org\/10.1136\/bmj.39323.586123.BE","journal-title":"BMJ"},{"key":"4145_CR6","unstructured":"Protocol Template to Be Used as Template for Observational Study Protocols for Cohort Event (2025) Monitoring (CEM) for Safety Signal Detection after Vaccination with COVID-19 Vaccines. Available online: https:\/\/www.who.int\/publications\/i\/item\/9789240027398 (accessed on 22 December)"},{"key":"4145_CR7","doi-asserted-by":"publisher","first-page":"e0005080","DOI":"10.1371\/journal.pgph.0005080","volume":"5","author":"DB Odhiambo","year":"2025","unstructured":"Odhiambo DB, Akech D, Karia B, Kimani M, Sang S, Sigilai A, Voller S, Mataza C, Mang\u2019ong\u2019o D, Jalang\u2019o R et al (2025) Active Vaccine Safety Surveillance: Experience from a Prospective Cohort Event Monitoring Study of COVID-19 Vaccines in Kenya. PLOS Glob Public Health 5:e0005080. https:\/\/doi.org\/10.1371\/journal.pgph.0005080","journal-title":"PLOS Glob Public Health"},{"key":"4145_CR8","doi-asserted-by":"publisher","first-page":"126460","DOI":"10.1016\/j.vaccine.2024.126460","volume":"42","author":"DM Darko","year":"2024","unstructured":"Darko DM, Seaneke SK, Karikari-Boateng E, Nkansah E, Amponsa-Achiano K, Mohamed NT, Bonful HA, Buabeng RO, Ashie A, Asamoa-Amoakohene A et al (2024) Safety of mRNA COVID-19 Vaccines among Persons 15- Years and above in Ghana: A Cohort Event Monitoring Study. Vaccine 42:126460. https:\/\/doi.org\/10.1016\/j.vaccine.2024.126460","journal-title":"Vaccine"},{"key":"4145_CR9","doi-asserted-by":"publisher","first-page":"126907","DOI":"10.1016\/j.vaccine.2025.126907","volume":"52","author":"O Bolu","year":"2025","unstructured":"Bolu O, Alo OD, Iwara E, Longley AT, Hadley I, Ogar CK, Ezekwe C, Elemuwa U, Adedokun O, Ramadhani HO et al (2025) Feasibility of Cohort Event Monitoring and Assessment of Reactogenicity and Adverse Events among a Cohort of AstraZeneca and Moderna COVID-19 Vaccine Recipients in Nigeria, 2021. Vaccine 52:126907. https:\/\/doi.org\/10.1016\/j.vaccine.2025.126907","journal-title":"Vaccine"},{"key":"4145_CR10","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1007\/s40264-025-01547-4","volume":"48","author":"C Sankar","year":"2025","unstructured":"Sankar C, Evans S, Meyer JC, Gunter HM, Sekiti V, McCarthy K (2025) Signal Monitoring for Adverse Events Following Immunisation with COVID-19 Vaccines During the SARS-CoV-2 Pandemic: An Evaluation of the South African Surveillance System. Drug Saf 48:909\u2013922. https:\/\/doi.org\/10.1007\/s40264-025-01547-4","journal-title":"Drug Saf"},{"key":"4145_CR11","doi-asserted-by":"publisher","unstructured":"Hagos AA, Sahile Z, Ahmed W, Phanouvong S. Leveraging COVID-19 vaccine safety monitoring in Ethiopia and Pakistan to enhance system-wide safety surveillance. Global Health: Science and Practice. 2024;12(Suppl 1):e2300161. https:\/\/doi.org\/10.9745\/GHSP-D-23-00161","DOI":"10.9745\/GHSP-D-23-00161"},{"key":"4145_CR12","doi-asserted-by":"publisher","first-page":"3623","DOI":"10.1016\/j.vaccine.2013.05.027","volume":"31","author":"HS Izurieta","year":"2013","unstructured":"Izurieta HS, Zuber P, Bonhoeffer J, Chen RT, Sankohg O, Laserson KF, Sturkenboom M, Loucq C, Weibel D, Dodd C et al (2013) Roadmap for the International Collaborative Epidemiologic Monitoring of Safety and Effectiveness of New High Priority Vaccines. Vaccine 31:3623\u20133627. https:\/\/doi.org\/10.1016\/j.vaccine.2013.05.027","journal-title":"Vaccine"},{"key":"4145_CR13","doi-asserted-by":"publisher","first-page":"1474045","DOI":"10.3389\/fmed.2024.1474045","volume":"11","author":"S Agampodi","year":"2024","unstructured":"Agampodi S, Tadesse BT, Sahastrabuddhe S, Excler J-L, Kim JH (2024) Biases in COVID-19 Vaccine Effectiveness Studies Using Cohort Design. Front Med (Lausanne) 11:1474045. https:\/\/doi.org\/10.3389\/fmed.2024.1474045","journal-title":"Front Med (Lausanne)"},{"key":"4145_CR14","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB et al (2021) Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med 384:403\u2013416. https:\/\/doi.org\/10.1056\/NEJMoa2035389","journal-title":"N Engl J Med"},{"key":"4145_CR15","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, P\u00e9rez Marc G, Moreira ED, Zerbini C et al (2020) Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med 383:2603\u20132615. https:\/\/doi.org\/10.1056\/NEJMoa2034577","journal-title":"N Engl J Med"},{"key":"4145_CR16","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1586\/17512433.2015.1053391","volume":"8","author":"S Olsson","year":"2015","unstructured":"Olsson S, Pal SN, Dodoo A (2015) Pharmacovigilance in Resource-Limited Countries. Expert Rev Clin Pharmacol 8:449\u2013460. https:\/\/doi.org\/10.1586\/17512433.2015.1053391","journal-title":"Expert Rev Clin Pharmacol"},{"key":"4145_CR17","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1007\/s40264-015-0331-7","volume":"38","author":"CK Suku","year":"2015","unstructured":"Suku CK, Hill G, Sabblah G, Darko M, Muthuri G, Abwao E, Pandit J, Osakwe AI, Elagbaje C, Nyambayo P et al (2015) Experiences and Lessons From Implementing Cohort Event Monitoring Programmes for Antimalarials in Four African Countries: Results of a Questionnaire-Based Survey. Drug Saf 38:1115\u20131126. https:\/\/doi.org\/10.1007\/s40264-015-0331-7","journal-title":"Drug Saf"},{"key":"4145_CR18","doi-asserted-by":"publisher","unstructured":"Kiguba R, Olsson S, Waitt C. Pharmacovigilance in low-and middle-income countries: A review with particular focus on Africa. Br J Clin Pharmacol. 2023;89(2):491\u2013509. https:\/\/doi.org\/10.1111\/bcp.15193","DOI":"10.1111\/bcp.15193"},{"key":"4145_CR19","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/j.vaccine.2022.01.013","volume":"40","author":"L Rolfes","year":"2022","unstructured":"Rolfes L, H\u00e4rmark L, Kant A, van Balveren L, Hilgersom W, van Hunsel F (2022) COVID-19 Vaccine Reactogenicity - A Cohort Event Monitoring Study in the Netherlands Using Patient Reported Outcomes. Vaccine 40:970\u2013976. https:\/\/doi.org\/10.1016\/j.vaccine.2022.01.013","journal-title":"Vaccine"},{"key":"4145_CR20","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1056\/NEJMoa2110737","volume":"385","author":"G Witberg","year":"2021","unstructured":"Witberg G, Barda N, Hoss S, Richter I, Wiessman M, Aviv Y, Grinberg T, Auster O, Dagan N, Balicer RD et al (2021) Myocarditis after Covid-19 Vaccination in a Large Health Care Organization. N Engl J Med 385:2132\u20132139. https:\/\/doi.org\/10.1056\/NEJMoa2110737","journal-title":"N Engl J Med"},{"key":"4145_CR21","doi-asserted-by":"publisher","first-page":"2202","DOI":"10.1056\/NEJMoa2105385","volume":"384","author":"M Scully","year":"2021","unstructured":"Scully M, Singh D, Lown R, Poles A, Solomon T, Levi M, Goldblatt D, Kotoucek P, Thomas W, Lester W (2021) Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination. N Engl J Med 384:2202\u20132211. https:\/\/doi.org\/10.1056\/NEJMoa2105385","journal-title":"N Engl J Med"},{"key":"4145_CR22","doi-asserted-by":"publisher","first-page":"e0246540","DOI":"10.1371\/journal.pone.0246540","volume":"16","author":"T Vanni","year":"2021","unstructured":"Vanni T, Thom\u00e9 BdaC, Oliveira MMM (2021) Active Pharmacovigilance of the Seasonal Trivalent Influenza Vaccine Produced by Instituto Butantan: A Prospective Cohort Study of Five Target Groups. PLoS ONE 16:e0246540. https:\/\/doi.org\/10.1371\/journal.pone.0246540. Gatt\u00e1sV.L.Salom\u00e3o, M. da G.; Koike, M.E.; Lucchesi, M.B.B.; Braga, P.E.; Piorelli, R. de O.; Viscondi","journal-title":"PLoS ONE"},{"key":"4145_CR23","doi-asserted-by":"publisher","first-page":"102663","DOI":"10.1016\/j.jaut.2021.102663","volume":"121","author":"A Dotan","year":"2021","unstructured":"Dotan A, Shoenfeld Y (2021) Perspectives on Vaccine Induced Thrombotic Thrombocytopenia. J Autoimmun 121:102663. https:\/\/doi.org\/10.1016\/j.jaut.2021.102663","journal-title":"J Autoimmun"},{"key":"4145_CR24","doi-asserted-by":"publisher","unstructured":"Izem, R., McCarter, R. Randomized and non-randomized designs for causal inference with longitudinal data in rare disorders. Orphanet J Rare Dis 16, 491 (2021) https:\/\/doi.org\/10.1186\/s13023-021-02124-5","DOI":"10.1186\/s13023-021-02124-5"},{"key":"4145_CR25","unstructured":"Huihui FS, Albert-Jesus (2025) Kseniya Bieliaieva,Marquez, Patricio Vicente,Wang Pharmacovigilance in Brazil : Creating an Effective System in a Diverse Country Available online: https:\/\/documents.worldbank.org\/en\/publication\/documents-reports\/documentdetail\/099806308102324619 (accessed on 22 December)"},{"key":"4145_CR26","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1002\/nur.22220","volume":"45","author":"L Stansert Katzen","year":"2022","unstructured":"Stansert Katzen L, Skeen S, Dippenaar E, Laurenzi C, Notholi V, le Roux K, Rotheram-Borus MJ, le Roux I, Mbewu N, Tomlinson M (2022) Are We Listening to Community Health Workers? Experiences of the Community Health Worker Journey in Rural South Africa. Res Nurs Health 45:380\u2013389. https:\/\/doi.org\/10.1002\/nur.22220","journal-title":"Res Nurs Health"},{"key":"4145_CR27","doi-asserted-by":"publisher","first-page":"215013192413067","DOI":"10.1177\/21501319241306706","volume":"16","author":"R Yousefi Nooraie","year":"2025","unstructured":"Yousefi Nooraie R, Naghibi D, Hern\u00e1ndez-Torres R, Cupertino PA (2025) Social Network Lens to Community Health Worker Influence and Impact. J Prim Care Community Health 16:21501319241306706. https:\/\/doi.org\/10.1177\/21501319241306706","journal-title":"J Prim Care Community Health"},{"key":"4145_CR28","doi-asserted-by":"publisher","first-page":"689","DOI":"10.2165\/11536390-000000000-00000","volume":"33","author":"S Olsson","year":"2010","unstructured":"Olsson S, Pal SN, Stergachis A, Couper M (2010) Pharmacovigilance Activities in 55 Low- and Middle-Income Countries: A Questionnaire-Based Analysis. Drug Saf 33:689\u2013703. https:\/\/doi.org\/10.2165\/11536390-000000000-00000","journal-title":"Drug Saf"},{"key":"4145_CR29","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s40264-019-00898-z","volume":"43","author":"A Barry","year":"2020","unstructured":"Barry A, Olsson S, Minzi O, Bienvenu E, Makonnen E, Kamuhabwa A, Oluka M, Guantai A, Bergman U, van Puijenbroek E et al (2020) Comparative Assessment of the National Pharmacovigilance Systems in East Africa: Ethiopia, Kenya, Rwanda and Tanzania. Drug Saf 43:339\u2013350. https:\/\/doi.org\/10.1007\/s40264-019-00898-z","journal-title":"Drug Saf"},{"issue":"Suppl 2","key":"4145_CR30","doi-asserted-by":"publisher","first-page":"B108","DOI":"10.1016\/j.vaccine.2012.10.119","volume":"31","author":"A Amarasinghe","year":"2013","unstructured":"Amarasinghe A, Black S, Bonhoeffer J, Carvalho SMD, Dodoo A, Eskola J, Larson H, Shin S, Olsson S, Balakrishnan MR et al (2013) Effective Vaccine Safety Systems in All Countries: A Challenge for More Equitable Access to Immunization. Vaccine 31(Suppl 2):B108\u2013114. https:\/\/doi.org\/10.1016\/j.vaccine.2012.10.119","journal-title":"Vaccine"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04145-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-026-04145-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04145-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T06:55:31Z","timestamp":1787036131000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-026-04145-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["4145"],"URL":"https:\/\/doi.org\/10.1007\/s00228-026-04145-0","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]},"assertion":[{"value":"10 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Participants and schoolchildren whose parents\/guardians agreed to participate and who provided oral consent and assent (age\u2009>\u2009=\u200912 years) were recruited in the study. Participation was voluntary and confidentiality was maintained.","order":1,"name":"Ethics","label":"Informed Consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This active surveillance was approved by the Addis Ababa University College of Health Sciences, School of Pharmacy ethics review committee (Ref no. ERB\/SOP\/3465A\/13\/2021) before its commencement and the study was conducted in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards Data collectors were trained on the protocol and data collection tools before commencement of the study. Basic information about the study objective, its significance, and procedures was provided to participants and parents\/guardians (for children\u2009>\u2009=\u200912 years of age) before enrolment.","order":3,"name":"Ethics","label":"Institutional Review Board Statement","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"216"}}